<DOC>
	<DOCNO>NCT02464384</DOCNO>
	<brief_summary>Multicenter , prospective , open-label , cohort study . Primary objective : Determination predictive value US alone combination cartilage biodegradation marker radiographic progression ( change Ratingen score ) Secondary objective : - Correlation ultrasound synovitis score clinical disease activity score - Determination sensitivity ultrasound erosion detection compare MRI - Assessment value include tenosynovitis assessment predict radiographic progression - Assessment predictive value ultrasound synovitis score baseline need install biologic DMARDs</brief_summary>
	<brief_title>Prediction Erosive Disease Early Rheumatoid Arthritis ( RA ) Ultrasound Cartilage Biodegradation Markers</brief_title>
	<detailed_description>Multicenter , prospective , open-label , cohort study collection blood sample ultrasound / MRI x-ray examination . Duration study : 12 month This study prospective cohort study . The choice therapy time study entirely treat rheumatologist . The study put restriction management patient accord routine care . At occurrence one mention variable define adverse clinical outcome ( prednisone dose exceed 10mg/d and/or intraarticular steroid injection and/or start biologic DMARD ) analysis D360 perform US-Score : SONAR-Score assessment synovitis ( 22 joint ) /erosions ( 14 joint ) /cartilage thickness ( 8 joint ) Clinical evaluation : Disease activity score ( DAS28 = Number tender swollen joint ( 0-28 ) , additional measure ( ESR / CRP ) , Patient Global Health ( 0-100 ) , health assessment questionnaire ( HAQ ) 0 , 3 , 6 , 9 , 12 month ( attach ) Lab : ESR , CRP Serology : Antinuclear antibody ( ANA ) , Rheumatoid factor ( RF ) , Anti-cyclic citrullinated peptide ( anti-CCP ) baseline available COL2-1 / COL2-1N X-Ray : hand foot baseline 12 month ( score accord Ratingen Score ) available MRI without contrast baseline 12 month first erosion detect US</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients fulfil follow inclusion criterion may enrol study : male female subject , Age 18 yr recent onset RA fulfil American College Rheumatology ( ACR ) criterion ( revised 2010 ) Symptoms least 6 week previous DMARD treatment intraarticular steroid injection last 4 week inclusion treatment oral steroid exceed equivalent 10mg prednisone per day last 2 week inclusion sign Informed Consent inform History inflammatory joint disease RA History active Tbc , histoplasmosis listeriosis History lymphoma malignancy within 5 year Contraindication use DMARD 's biologics Comorbidities : severe myocardial dysfunction , recent stroke ( within 3 month ) , uncontrolled diabetes disease opinion investigator , would put subject risk participation trial History demyelinating disorder persistent recurrent infection Pregnancy breast feeding inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ultrasound cartilage biodegradation marker</keyword>
</DOC>